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The triglyceride glucose index can predict newly
diagnosed biopsy-proven diabetic nephropathy in
type 2 diabetes
A nested case control study
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Abstract
Insulin resistance is usually a key factor in the development of type 2 diabetes. The triglyceride glucose (TyG) index is a marker of
insulin resistancewhich is also implicated in the risk of nephropathy amongpeople with type 2 diabetes. This study aimed to examine
associations and potential thresholds between TyG index and the risk of newly diagnosed biopsy-proven diabetic nephropathy in
peoplewith type 2 diabetes. A nested case–control study incorporating 950 incident biopsy-proven diabetic nephropathy cases and
age, gender matched 4750 patients with treated type 2 diabetes as controls selected by risk-set sampling method was
implemented. The dose–response association between TyG indexwith subsequent risk of newly diagnosed biopsy-proven diabetic
nephropathy after adjustment for age, gender, blood pressure, and other major cardiovascular risk factors were examined by
conditional logistic regression model. A non-linear relationship was identiﬁed between TyG index and the risk of newly diagnosed
biopsy-proven diabetic nephropathy with a potential threshold of TyG at 9.05–9.09. Similar relationships with the same threshold
were also found in the analyses by fasting glucose and triglyceride levels. TyG index might be a prognostic factor in predicting newly
development of biopsy-proven diabetic nephropathy among patients with treated type 2 diabetes. In people with type 2 diabetes,
TyG index above 9.05–9.09 could be a prognostic threshold to identify individuals at high risk of diabetic nephropathy. Further
replication studies are warranted.
Abbreviations: DN = diabetic nephropathy, eGFR = estimated glomerular ﬁltration rate, HOMA-IR = homeostasis model
assessment of insulin resistance, IR = insulin resistance, TyG= triglyceride glucose index, UKPDS=UK Prospective Diabetes Study.
Keywords: diabetes, diabetic nephropathy, insulin resistance, prognosis, TyG index
1. Introduction
Diabetic nephropathy (DN) is the leading cause of chronic kidney
disease in patients initialising renal replacement therapy, and is
associated with increased cardiovascular mortality.[1,2] In the UK
Prospective Diabetes Study (UKPDS), the randomized controlled
trial of glycemic management of newly diagnosed type 2 diabetes,
the annual incidence of clinically diagnosed DN was 2.0% with a
10-year prevalence of 25%.[3] DN is more common in Asian
populations.[4] It has been estimated that in the1990s,DNdoubled
as an indication for initializing renal replacement therapy.[5]
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Insulin resistance (IR) has been reported to be associated with
an increased risk of developing progressive DN among patients
with diabetes, but only in cross-sectional studies.[6,7] Some
prospective studies have also reported that IR may precede and
predict microalbuminuria in patients with diabetes.[8] Further-
more, the frequency of factors associated with IR, like
hypertension, central obesity, and dyslipidaemia also increase
as DN progresses.[6] However, prospective studies demonstrating
that IR contributes to the development and progression of DN in
type 2 diabetes are yet to be reported, probably due to the cost of
insulin measurement and required study duration.
Several recent studies have shown that the triglyceride glucose
(TyG) index is associated with IR,[9,10] assessed by both
hyperinsulinemic euglycemic clamp testing and homeostasis
model assessment of insulin resistance (HOMA-IR). The clamp is
considered as the gold standard method for measuring IR.[12] But
the clamp method is complex and not used in clinical practice, as
it involves a primed-continuous infusion of insulin administered
to raise the plasma insulin concentration to a predetermined
physiological or pharmacological level. The plasma glucose
concentration is then measured at 5-min intervals with a variable
infusion of exogenous glucose administered to maintain the
plasma glucose concentration constant at the fasting level. Since
the plasma glucose concentration remains unchanged, the
amount of exogenous glucose infused must equal the amount
of glucose utilized in response to the hyperinsulinemia and, thus,
provides a direct measure of whole-body sensitivity to insulin.[11]
The other, more widely usedHOMA-IR is calculated as (fasting
plasma insulin level [in mU/mL]  fasting plasma glucose level [in
mmol/L])/22.5. A value of 1.00 is considered normal and higher
values indicate progressively severe states of IR. This method is
much more variable than the clamp due to the wide range of
“normal” values for fasting plasma insulin. Also, it cannot be used
in patients with diabetes, where the normal homeostatic relation-
ship between plasma glucose and insulin levels no longer exists. It
has theoretical limitations based on the fact that it attempts to
measure insulin sensitivity in the fasting state when the majority of
glucose uptake is independent of insulin. Thus, the TyG index has
shown direct correlation with IR and been proposed as a reliable
and simple surrogate marker of IR in clinical practice.[13,14]
Consistent with these data, there is growing evidence to suggest
that the TyG index is associatedwith cardiovascular disease.[15–17]
However, to the best of our knowledge, few studies have
examined the relationship between the TyG index and the risk
of development of DN among patients with type 2 diabetes.
Therefore, in the present study, we have investigated the
relationship between the TyG index and risk of newly diagnosed
biopsy-proven DN among patients with type 2 diabetes.
2. Materials and methods
2.1. Data setting
We conducted this nested case–control study in Zhengzhou,
Henan, China, which has 109 million residents. Both cases and
controls were enrolled in the First Afﬁliated Hospital, Zhengzhou
University, which is the largest hospital in China and provides
both primary and secondary care to Henan residents. Health
insurance coverage has been 90% since 2008, allowing most
patients with DN to be diagnosed during a hospital admission. As
the provincial renal center, most renal biopsies among patients
with diabetes were processed in the hospital.
2.2. Case deﬁnition
A total of 950 patients with type 2 diabetes who were newly
diagnosed with DN at the First Afﬁliated Hospital, Zhengzhou
University between February 1, 2012 and February 28, 2018
were included in this study. The diagnosis of diabetes for cases
and controls was based on the American Diabetes Association
criteria.[18] The diagnosis of DN was made based on histological
characteristics, such as glomerular hypertrophy, thickened
capillary basement membranes, diffuse mesangial expansion
(sclerosis), nodular mesangial sclerosis, exudative lesions such as
capsular drop or ﬁbrin cap, mesangiolysis, mescapillary micro-
aneurysm, or hyalinosis of afferent and efferent arterioles, using
appropriate standard for renal biopsy including light microscopy,
electron microscopy, and immunoﬂuorescence examination.[9]
Patients with other glomerular diseases concomitant with DN
were excluded from this study. Renal biopsy was performed for
precise diagnosis of renal lesions with the consent of each patient.
2.3. Matched controls
We used the inpatient administration system to select 5 controls
for each case, matched for age and gender. Controls were patients
with type 2 diabetes who attended outpatient departments or
were admitted to the hospital between January 1, 2016 and
December 31, 2017. Patients with estimated glomerular ﬁltration
rate (eGFR) <90mL/min/1.73 m2 and urine total protein >30
mg/24h were excluded.[9,19] Controls were selected using a risk
set sampling method,[10] by which the odds ratios estimated the
incidence rates ratios. Controls were assigned an index date
identical to that of corresponding cases.
2.4. Exposure deﬁnition
TyG index was calculated as the ln[fasting triglyceride (mg/dL)
fasting glucose (mg/dL)/2].[20] In the dose–response analysis
between TyG and risk of DN, TyG was treated as continuous
variable. To understand the outcome distribution further, a
histogram is shown of incidence rates ratios of outcome by TyG
quartile group (Supplemental Figure S1, http://links.lww.com/
MD/D371): Group 1 (TyG index<8.60), Group 2 (TyG index in
8.60–9.09); Group 3 (TyG index in 9.09–9.60), and Group 4
(TyG index ≥ 9.60).
2.5. Ethics approval
Ethics approval was granted by the Clinical Research Ethics
Committee of the First Afﬁliated Hospital of Zhengzhou
University. Written informed consent was obtained from all
participants before inclusion.
2.6. Co-variables and missing information
There was missing information on body mass index (56.2%),
systolic blood pressure (37.4%), diastolic blood pressure
(38.2%), fasting glucose (6.1%), HbA1c (6.7%), hematocrit
(13.6%), mean corpuscular hemoglobin (13.6%), mean platelet
volume (13.6%), monocyte (13.6%), red blood cell distribution
width (13.6%), magnesium (22.1%), sodium (22.1%), chlorine
(22.1%), activated partial thromboplastin time (32.8%), D-
Dimer (32.8%), thrombin time (32.8%), ﬁbrinogen (32.8%), and
ﬁbrinogen degradation products (32.8%). Multiple imputations
were applied to replace missing values by using a chained
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equation method based on all candidate predictors and primary
outcome. Fifty-six imputed datasets were generated for missing
predictors that were then combined across all datasets by using
Rubin’s rule to generate ﬁnal model estimates.[21]
2.7. Statistical analysis
In descriptive analyses, differences in participant characteristics
by TyG index categories were assessed by logistic regression
model for categorical variables, and generalized linear model for
continuous variables.
Newly diagnosed biopsy-proven DN was deﬁned as a binary
outcome measure. A conditional logistic regression model was
used to estimate the crude and adjusted incidence rates ratios of
newly diagnosed biopsy-proven DN by TyG index categories.
The dose–response relationships between TyG index and risks of
newly diagnosed biopsy-proven DNwere estimated using a linear
model, a natural cubic spline model with three equally spaced
knots determined from the levels of TyG index measures, and a
quadratic spline model. The natural cubic spline model was
chosen as the best ﬁt model for the relationship curve by its
minimum Akaike information criterion (AIC) compared with the
linear model or quadratic spline model. The linear test was used
in the natural cubic spline model to test the linearity of the
relationship. The break-point test[22] was carried out to target the
potential thresholds (P5 to P95 of TyG index measures) by
incorporating the piecewise term into the cubic spline model. The
threshold with a signiﬁcant break in the regression coefﬁcients
and achieving the minimum AIC was chosen as the ﬁnal
threshold.[23] The 95% CI of the threshold was obtained from
1000 bootstrap samples. The associations between the TyG index
and the risk of newly diagnosed biopsy-proven DN below and
above the threshold were analysed such that the TyG index was
treated as a continuous variable to observe the risk of DN with
each 1 unit increase of the TyG index.
In the sensitivity analyses, the dose–response association
between the TyG index and risk of DN was re-analyzed by the
level of confounders (glucose and triglyceride) to examine
whether the dose–response associations were consistent with
those found in the main analyses. At each level of confounders,
we also quantiﬁed the association between TyG index and risk of
DN below and above threshold.
All analyses were performed using STATA (STATA/MP 15.0
StataCorp, College Station, TX). All P values were calculated
using two-tailed tests and a P value < .05 was taken to indicate
statistical signiﬁcance. All methods were performed in accor-
dance with the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guidelines.
3. Results
Potential prognostic factors measured in cases and controls are
shown in Table 1. Cases with newly diagnosed biopsy-proven
DN had lower levels of hemoglobin, mean corpuscular
hemoglobin, lymphocyte, monocyte, total bile acid, high density
lipoprotein cholesterol, calcium, carbon dioxide combining
power and eGFR, and higher levels of the remaining factors.
A non-linear (“J-shape”) relationship was found between TyG
index and risk of development of newly diagnosed biopsy-proven
DN (P-values for linearity test < .0001). The dose–response
relationship was derived from the natural cubic spline model with
adjustment of covariables in Figure 1. In the sensitivity analysis
modeling the associations with fasting glucose and serum
triglyceride (fasting glucose <8.0 mmol/L and fasting glucose
≥8.0mmol/L; triglyceride <1.5mmol/L and triglyceride ≥1.5
mmol/L), similar dose–response relationships were identiﬁed by
fasting glucose level (Figure 1) and by serum triglyceride level
(Figure 2). The individual-level incidence rates ratio distribution
in four TyG categories based on the quartile of TyG (Group-1:
TyG 8.60; Group-2: TyG 8.60<TyG 9.09; Group-3: 9.09<
TyG9.60; and Group-4: TyG > 9.60) were presented in
Supplemental Figure S1, http://links.lww.com/MD/D371, which
indicated most patients’ incidence rates ratio covering the
estimated range of risk of DN shown in Figure 1.
A TyG index below 9.07 (95% conﬁdence interval: 9.05–9.09)
was estimated to be associated with the lowest risk of newly
diagnosed biopsy-proven DN, as tested by linear threshold
models. The thresholds were the same with fasting glucose levels
and serum triglyceride levels. Table 2 shows that the risks of
newly diagnosed biopsy-proven DN increase signiﬁcantly with
each 1 unit increase of TyG index above the TyG threshold (9.07)
overall and by glucose and triglyceride levels (except triglyceride
<1.5mmol/L): adjusted incidence rates ratio (IRR) per TyG index
unit for risk of newly diagnosed biopsy-proven DN 1.56 (95%
CI: 1.27–1.91, P< .0001) overall; adjusted IRR for risk of newly
diagnosed biopsy-proven DN 1.50 (1.09–2.06, P< .0001) in
those with glucose <8.0mmol/L and 2.06 (1.01–4.20, P
< .0001)) in those with glucose ≥ 8.0mmol/L; adjusted IRR
for risk of newly diagnosed biopsy-proven DN 0.99 (0.41–2.40,
P= .3562) in those with triglyceride <1.5mmol/L and 1.92
(1.10–3.34, P< .0001) in those with triglyceride ≥ 1.5mmol/L.
The risks of newly diagnosed biopsy-proven DN did not increase
signiﬁcantly with 1 unit increase of TyG index above the TyG
threshold overall and by glucose and triglyceride levels (Table 2).
4. Discussion
Our study was undertaken to relate TyG index, as a measure of
insulin resistance, to the risks of newly diagnosed biopsy-proven
DN in patients with type 2 diabetes.We focused our investigation
on the dose–response relationships assessing the evidence for a
nonlinear association, and for the existence of a threshold. In all
our analyses, we found evidence that the associations are
nonlinear. Threshold analysis provided evidence of a TyG index
threshold: 9.07 (9.05–9.09). The signiﬁcantly higher risks of
newly diagnosed biopsy-proven DN were found above 9.07 of
TyG index in people with type 2 diabetes.
Our investigation is the ﬁrst study to explore the association
between TyG index, as a surrogate for IR and the risk of newly
diagnosed biopsy-proven DN in people with type 2 diabetes. In
previous reports, a high TyG index had been found to be
associated with the risk of type 2 diabetes in the general
population,[24] with subclinical atherosclerosis and arterial
stiffness in postmenopausal women[25] and with the risk of
other diabetes related complications, such as coronary artery
stenosis[26] and Cardiac Autonomic Neuropathy.[27] Consistent
with these previous ﬁndings, we have found that a high TyG
index (in particular TyG index ≥ 9.07) is associated with a high
risk of DN,which is the leading cause of end-stage renal disease in
people with type 2 diabetes.
Non-linear dose–response relationships between TyG index
and non-DN outcomes have previously been shown. For
example, among patients with type 2 diabetes, a previous study
was found that compared with patients with TyG index at 8.2,
Shang et al. Medicine (2019) 98:46 www.md-journal.com
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Table 1
Clinical measurements among diabetic nephropathy cases and matched controls with type 2 diabetes.
Case Control P
N 950 4750 –
Female gender, n (%) 446 (46.91) 2230 (46.91) –
Age (years) 64 (55–73) 64 (54–72) –
Body mass index (kg/m2) 25.4 (23.1–28.6) 23.4 (20.8–25.0) .0001
Systolic blood pressure (mm Hg) 140.0 (131.5–147.1) 130.7 (123.0–138.9) .0001
Diastolic blood pressure (mm Hg) 79.0 (74.1–83.5) 76.3 (72.0–80.1) .0001
Antihypertensive treatment, n (%) 335 (35.3) 798 (16.8) .0001
Lowering lipid treatment, n (%) 113 (11.9) 508 (10.7) .5263
Insulin treatment, n (%) 797 (83.9) 3268 (68.8) .0001
HbA1c (%) 7.76 (6.60–9.06) 7.40 (6.27–8.62) .0001
Alanine transaminase (U/L) 39.90 (22.70–157.71) 35.00 (29.30–40.60) .0001
Alkaline phosphatase (IU/L) 78.87 (53.00–115.98) 78.50 (60.50–105.33) .0001
Activated partial thromboplastin time (s) 31.15 (27.60–35.80) 30.10 (26.40–34.68) .0001
Direct bilirubin (mmol/L) 4.62 (1.30–14.38) 3.60 (2.17–6.90) .0001
Basophil (%) 0.04 (0.02–0.05) 0.03 (0.02–0.05) .0001
Cholinesterase (U/L) 8.80 (1.97–33.26) 5.60 (1.58–18.08) .0001
Calcium (mmol/L) 2.16 (2.05–2.28) 2.24 (2.12–2.34) .0001
Chlorine (mmol/L) 102.00 (98.50–105.50) 101.88 (98.38–105.00) .0001
Creatinine (mmol/L) 159.00 (109.40–355.00) 63.00 (11.19–135.59) .0001
C reaction protein (mg/L) 22.81 (1.49–58.14) 21.06 (3.23–54.39) .0001
Cysteine proteinase inhibitor 2.18 (1.38–3.34) 0.91 (0.21–1.64) .0001
D_Dimer (mg/mL) 1.20 (0.69–2.16) 0.46 (0.09–2.22) .0001
Fibrinogen degradation products (mg/L) 5.72 (1.16–12.03) 3.26 (1.74–4.22) .0001
Fibrinogen (g/L) 3.90 (3.15–4.66) 3.44 (2.74–4.22) .0001
Gamma glutamyl transpeptidase (U/L) 35.00 (13.00–91.80) 29.50 (17.00–61.00) .0001
Globulin (g/L) 26.47 (22.82–30.30) 25.85 (22.20–29.60) .0001
Glucose (mmol/L) 7.98 (5.51–11.22) 7.89 (5.63–10.90) .0001
High density lipoprotein cholesterol (mmol/L) 0.97 (0.74–1.21) 1.04 (0.82–1.30) .0001
Hemoglobin (g/L) 101.00 (84.98–117.00) 119.00 (102.92–134.00) .0001
Hematocrit (%) 18.94 (3.80–29.00) 11.15 (3.80–2.346) .0001
Indirect Bilirubin (mmol/L) 5.24 (2.74–8.80) 3.40 (2.00–5.70) .0001
Potassium (mmol/L) 4.34 (3.95–4.80) 4.20 (3.77–4.62) .0001
Low density lipoprotein cholesterol (mmol/L) 2.50 (1.75–3.33) 2.47 (1.72–3.26) .0001
Lymphocyte (%) 1.56 (1.04–2.10) 1.30 (0.83–1.85) .0001
Mean corpuscular hemoglobin concentration (g/L) 326.75 (320.85–333.00) 329.44 (323.00–337.00) .0001
Mean corpuscular volume (fL) 90.60 (85.99–95.10) 90.40 (86.30–94.23) .0001
Magnesium (mmol/L) 0.95 (0.86–1.06) 0.91 (0.81–1.01) .0001
Mean platelet volume (fL) 8.90 (8.10–9.80) 8.83 (8.00–9.70) .0001
Monocytes (%) 0.59 (0.25–1.05) 0.56 (0.17–1.07) .0001
Sodium (mmol/L) 141.45 (138.35–144.37) 140.60 (137.60–143.23) .0001
Neutrophil (%) 6.70 (4.26–9.68) 5.56 (3.15–8.31) .0001
Phosphorus (mmol/L) 1.24 (1.05–1.47) 1.11 (0.90–1.31) .0001
Procalcitonin (ng/mL) 1.19 (0.10–1.42) 1.17 (0.27–1.86) .0001
Red blood cell (1012/L) 3.89 (1.00–10.99) 3.67 (2.67–10.05) .0001
Red blood cell distribution width (%) 14.60 (13.60–15.90) 13.94 (13.00–15.37) .0001
Total cholesterol (mmol/L) 4.12 (3.21–5.13) 4.05 (3.16–5.01) .0001
Total bile acid (mmol/L) 5.69 (2.37–17.67) 4.10 (1.04–13.82) .0001
Total bilirubin (mmol/L) 10.14 (4.31–22.45) 7.55 (4.50–13.10) .0001
Triglyceride (mmol/L) 1.71 (1.06–2.67) 1.63 (0.89–2.62) .0001
Thyroid-stimulating hormone (mIU/mL) 2.62 (0.38–5.60) 2.25 (0.08–5.31) .0001
Urine acid (mmol/L) 351.00 (278.40–435.28) 250.99 (179.79–328.00) .0001
Thrombin time (s) 15.30 (13.58–17.70) 14.60 (12.32–17.32) .0001
Urea (mmol/L) 11.70 (7.85–18.30) 5.10 (2.45–8.07) .0001
White blood cell count (109/L) 7.99 (5.00–16.14) 6.40 (1.98–21.00) .0001
estimated glomerular ﬁltration rate (mL/min/1.73 m2) 35.79 (14.35–53.42) 94.93 (90.17–108.39) .0001
Carbon dioxide combining power (mmol/L) 23.00 (20.40–25.65) 24.81 (22.20–27.33) .0001
Urine total protein (mg/24 h) 597.50 (66.90–2255.70) 4.68 (1.28–7.98) .0001
a-Microglobulin (mg/L) 53.12 (31.00–80.23) 25.88 (5.62–46.74) .0001
b2-Microglobulin (mg/L) 6.78 (3.75–9.97) 1.74 (0.27–4.00) .0001
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people with TyG index at 8.9 had a higher risk of coronary artery
stenosis and this risk signiﬁcantly increased among those with a
TyG index of 9.7.[26] In another study, in the general population,
compared with people whose TyG index was below 8.21, the risk
of incident type 2 diabetes signiﬁcantly increased with a TyG
index of 8.21 to 5.56, plateaued and then increased at a TyG
index > 8.97.[24] However, in those studies, the TyG index was
modeled as a categorical variable grouped by percentiles, a
method no longer recommended as it is found to be less
informative.[28] In our study, TyG was modeled as a continuous
variable, applying a ﬂexible cubic spline regression model to
derive a more accurate dose–response relationship, “J-shape”
and a convincible threshold, TyG at 9.05 to 9.09 for future
replications and clinical practice.
Themechanism behind the association between TyG index and
risk of newly diagnosed biopsy-proven DN could be the
Figure 1. The dose–response association between TyG and risk of biopsy-proven diabetic nephropathy overall and by fasting glucose level. Body mass index,
systolic blood pressure, diastolic blood pressure, antihypertensive treatment, lowering lipid treatment, insulin treatment, HbA1c, alanine transaminase, alkaline
phosphatase, activated partial thromboplastin time, direct bilirubin, Basophil, cholinesterase, calcium, chlorine, creatinine, C reaction protein, cysteine proteinase
inhibitor, D_Dimer, ﬁbrinogen Degradation Products, gamma glutamyl transpeptidase, globulin, glucose, high density lipoprotein cholesterol, hemoglobin,
hematocrit, indirect Bilirubin, potassium, low density lipoprotein cholesterol, lymphocyte, mean corpuscular hemoglobin concentration, mean corpuscular volume,
magnesium, mean platelet volume, monocytes, sodium, neutrophil, phosphorus, procalcitonin, red blood cell, red blood cell distribution width, total cholesterol,
total bile acid, total bilirubin, triglyceride, thyroid-stimulating hormone, urine acid, thrombin time, white blood cell count, estimated glomerular ﬁltration rate, carbon
dioxide combining power, urine total protein, a-microglobulin, b2-microglobulin were adjusted.
Figure 2. The dose–response association between TyG and risk of biopsy-proven diabetic nephropathy by triglyceride level. Body mass index, systolic blood
pressure, diastolic blood pressure, antihypertensive treatment, lowering lipid treatment, insulin treatment, HbA1c, alanine transaminase, alkaline phosphatase,
activated partial thromboplastin time, direct bilirubin, Basophil, cholinesterase, calcium, chlorine, creatinine, C reaction protein, cysteine proteinase inhibitor,
D_Dimer, ﬁbrinogen Degradation Products, gamma glutamyl transpeptidase, globulin, glucose, high density lipoprotein cholesterol, hemoglobin, hematocrit,
indirect Bilirubin, potassium, low density lipoprotein cholesterol, lymphocyte, mean corpuscular hemoglobin concentration, mean corpuscular volume, magnesium,
mean platelet volume, monocytes, sodium, neutrophil, phosphorus, procalcitonin, red blood cell, red blood cell distribution width, total cholesterol, total bile acid,
total bilirubin, triglyceride, thyroid-stimulating hormone, urine acid, thrombin time, white blood cell count, estimated glomerular ﬁltration rate, carbon dioxide
combining power, urine total protein, a-microglobulin, b2-microglobulin were adjusted.
Shang et al. Medicine (2019) 98:46 www.md-journal.com
5
progression of IR in people with type 2 diabetes.[29] Previous
ﬁndings suggest that the deteriorated IR in people with type 2
diabetes is associated with signiﬁcantly changed levels of
hormone, like parathyroid hormone,[30] cortisol,[31] peptide
hormone[32,33] that could lead to microalbuminuria and declined
eGFR in people with type 2 diabetes.
Our ﬁndings have some potential implications for the clinical
practice. First, this dose–response relationship and especially the
threshold found in our study could be used as a prognostic index
in clinical practice to identify potentially high-risk individuals
that could warrant more intensive treatment to postpone the
progress of DN. In practical terms, the need to reduce and then
cease metformin, an insulin sensitizer, could accelerate progres-
sion to end-stage renal disease.[34] The careful use of a
thiazolidinedione, while monitoring for and avoiding ﬂuid
overload, could be a strategy to reduce progression while
maintaining euglycemia.[35] Finally, while the clinical utilisation
of HOMA is restricted by its cost and lack of utility in insulin-
treated diabetes, the TyG Index, ameasurement of fasting glucose
and triglycerides, could be used as a marker of IR.[20,36] This
index has the advantage of being clinically applicable as both
triglyceride and glucose concentrations are inexpensive and
routinely measured in those with diabetes.[20]
Our study has some limitations. First, the control population
were patients admitted to hospital, and therefore unlikely to be
representative of the Chinese type 2 diabetes population.
However, those with DN were also hospital patients, partly
because there are no distinctive differences between primary and
secondary care settings in China. The potential selection bias in
our study would therefore be lower than in settings without this
continuum. Future validation studies are warranted in other type
2 diabetes populations, including those from ambulatory care
(primary and secondary). Secondly, the proportion of people
with missing data was signiﬁcant, particularly for some
covariables. Although our analyses were carried out using
imputed datasets, further validation studies with datasets with
less missing data are also warranted.
In summary, we have identiﬁed a non-linear relationship
between the TyG index, a proxy for IR, and risk of newly
diagnosed biopsy-proven DN in people with type 2 diabetes. The
TyG index threshold of 9.05 to 9.09 may be useful for identifying
high-risk individuals for further intensive intervention. These
ﬁndings may suggest a greater role for insulin sensitizers in the
prevention of DN. Further replication studies are warranted.
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